BANGALORE, India & IRVINE, Calif.–(BUSINESS WIRE)– Masimo heeft vandaag bekendgemaakt dat Motherhood Hospitals, een kraamzorgspecialist met vijf ziekenhuizen in drie Indiase steden, Masimo SET als standaardsysteem voor pulse-oxymetrie heeft ingevoerd. Motherhood Hospitals voert met Masimo’s technologie ook controles op aangeboren hartafwijkingen uit.
“We hebben verschillende technologieën beoordeeld en vonden dat Masimo SET zelfs in de meest uitdagende omstandigheden het betrouwbaarst bleef”, zei Mohammed Rehan Sayeed, topman van Motherhood Hospitals. “Dit gehele standaardiseringsproces is geïnitieerd door het medische personeel.”
One of India’s Premier Maternal Care Specialists, Motherhood Hospitals, Standardizes on Masimo SET® Technology
BANGALORE, India & IRVINE, Calif.–(BUSINESS WIRE)– Masimo (NASDAQ: MASI) announced today that Motherhood Hospitals, a maternal care specialist with five hospitals in three cities in India, has standardized on Masimo SET ® (Signal Extraction Technology) pulse oximetry at all locations. Motherhood Hospitals will also be screening for Critical Congenital Heart Disease (CCHD) using Masimo’s technology.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160602005492/en/
“We evaluated several technologies and found Masimo SET pulse oximetry to be the most reliable even in the most challenging conditions,” said Dr. Mohammed Rehan Sayeed, Chairman, Motherhood Hospitals. “This entire standardization exercise was driven by the clinical staff.”
Masimo SET ® Measure-through Motion and Low Perfusion™ pulse oximetry measures oxygen saturation (SpO 2), pulse rate (PR), and perfusion index (PI), and helps clinicians monitor more than an estimated 100 million patients a year. 1 In a study of newborns, researchers found CCHD was identified by physical examination alone 63% of the time, and when Masimo SET ® pulse oximetry was added to the physical exam screening, researchers found that clinicians were able to identify CCHD 83% of the time–a 31% increase. 2
“We are happy to see the team at Motherhood Hospitals, which conducts research into how to improve the health and well-being of neonates in India, select our SET technology,” said Joe Kiani, Founder and CEO of Masimo. “We hope to work with Motherhood Hospitals to standardize universal screening for CCHD in newborns. We are seeing more and more hospitals in this region of the world realize the important role reliable pulse oximetry plays in patient care and safety.”
Motherhood Hospitals, a premium birthing boutique, provides a variety of services to expecting women and newborns in India, specializing in obstetrics, gynecology, neonatology, pediatrics, fetal medicine, fertility, and cosmetology. At their combined locations in Bangalore, Chennai, and Hyderabad, they perform over 6,000 deliveries annually.
@MasimoInnovates | #Masimo
|1||Masimo data on file.|
|2||de-Wahl Granelli A, Wennergren M, Sandberg K, Mellander M, Bejlum C, Inganäs L, Eriksson M, Segerdahl N, Agren A, Ekman-Joelsson BM, Sunnegårdh J, Verdicchio M, Ostman-Smith I. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009 Jan 8;338:a3037.|
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET ® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET ® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb ®), oxygen content (SpOC™), carboxyhemoglobin (SpCO ®), methemoglobin (SpMet ®), and more recently, Pleth Variability Index (PVI ®) and Oxygen Reserve Index (ORI™), in addition to SpO 2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root ®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SET ®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique noninvasive measurement technologies, including Masimo SET ®, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Irene Paigah, 858-859-7001